
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Supplements and Featured Publications
about 22 years ago
CME/CE Quizabout 22 years ago
The Debateabout 22 years ago
Defining the Great Debate




